No Data
No Data
12 Health Care Stocks Moving In Thursday's After-Market Session
Exicure Close to Finishing Patient Recruitment in Phase 2 Study of GPC-100 in Multiple Myeloma
Express News | Reported Friday, Exicure Advances GPC-100 Into AML With New Trial Plans, Building On Prior Chemosensitization Study
Express News | Exicure, Inc. (Nasdaq: Xcur) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (Aml)
Major Investment Alert: HiTron Systems Inc. Boosts Stake in Exicure!
HiTron Systems Acquires $8.7 Million in Exicure Stock